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Resistance against currently used antitubercular therapeutics in-
creasingly undermines efforts to contain the worldwide tubercu-
losis (TB) epidemic. Recently, benzothiazinone (BTZ) inhibitors
have shown nanomolar potency against both drug-susceptible
and multidrug-resistant strains of the tubercle bacillus. However,
their proposed mode of action is lacking structural evidence. We
report here the crystal structure of the BTZ target, FAD-containing
oxidoreductaseMycobacterium tuberculosis DprE1, which is essen-
tial for viability. Different crystal forms of ligand-free DprE1 reveal
considerable levels of structural ﬂexibility of two surface loops
that seem to govern accessibility of the active site. Structures of
complexes with the BTZ-derived nitroso derivative CT325 reveal
the mode of inhibitor binding, which includes a covalent link to
conserved Cys387, and reveal a triﬂuoromethyl group as a second
key determinant of interaction with the enzyme. Surprisingly, we
ﬁnd that a noncovalent complex was formed between DprE1 and
CT319, which is structurally identical to CT325 except for an inert
nitro group replacing the reactive nitroso group. This demon-
strates that binding of BTZ-class inhibitors to DprE1 is not strictly
dependent on formation of the covalent link to Cys387. On the
basis of the structural and activity data, we propose that the com-
plex of DrpE1 bound to CT325 is a representative of the BTZ-target
complex. These results mark a signiﬁcant step forward in the char-
acterization of a key TB drug target.
mycobacterial cell wall | X-ray crystallography | multi drug resistance |
arabinan | decaprenylphosphoryl-D-arabinose
For the past several decades, treatment of active tuberculosis(TB) infections has relied on a relatively small set of che-
motherapeutic agents, including the widely used front-line
drugs isoniazid, ethambutol, rifampicin, and pyrazinamide (1).
The lack of novel inhibitors of adequate efﬁcacy has favored
the emergence of multidrug-resistant (MDR) and extensive
drug-resistant (XDR) strains of the tubercle bacillus, drastically
increasing the cost and duration of treatment and threatening
to undermine World Health Organization-led efforts to contain
the global TB pandemic (2, 3). Responding to the urgent need
for new antibiotics, partnerships between academic institutions,
research charities, and industry have been able to feed a modest
pipeline of drug leads, with two candidates currently in phase
III clinical trials (4). However, more recently nitro-benzothia-
zinones (BTZs) have emerged as a promising class of inhibitors,
effective against both drug-susceptible and MDR/XDR strains
of Mycobacterium tuberculosis at signiﬁcantly lower minimum
inhibitory concentrations (MICs) than either isoniazid or ri-
fampicin, in combination with reduced toxicity (5, 6). The most
potent compound in this series to date, BTZ043 (Scheme 1A),
has an MIC of 1 ng/mL againstM. tuberculosis, 20-fold less than
that of isoniazid (5). A structurally related set of compounds,
dinitrobenzamides (DNBs), which includes N-(2-(4-methox-
yphenoxy) ethyl)-3,5-dinitrobenzamide (DNB1; Scheme 1A),
have likewise shown potency against XDR strains combined
with low toxicity (7).
BTZ and related compounds inhibit the conversion of decap-
renylphosphoryl-β-D-ribose (DPR) to decaprenylphosphoryl-β-D-
arabinofuranose (DPA; Scheme 1B), a precursor of mycobacterial
cell wall arabinan. This two-step epimerization reaction is cata-
lyzed by the joint or successive action of the FAD-containing
oxidoreductase DprE1 (Rv3790) and the NADH-dependent re-
ductase DprE2 (Rv3791) (Scheme 1B) (8). DPA is the sole known
donor substrate for a series of membrane-embedded arabinosyl-
transferases, including the ethambutol targets EmbC, EmbA, and
EmbB (9). Essentiality of DPA supply and lack of alternative
synthetic pathways position DprE1, which is highly conserved in
mycobacteria (Fig. S1A), and DprE2 at a critical intersection of
cell wall biosynthesis, a notion conﬁrmed by transposon muta-
genesis (10, 11). This situation has led some to speak of DprE1 as
a magic drug target (1).
BTZ and DNB class inhibitors both contain a central benzene
ring carrying a nitro group at position 3 (Scheme 1A). Inhibition
of DprE1 by BTZ/DNB inhibitors has been shown to require
conversion of the nitro to a nitroso group, proposed to form
a semimercaptal linkage with a conserved cysteine in the active
site of DprE1 (Cys387 in M. tubercuclosis) (12, 13). There has
been speculation that BTZ and DNB inhibitors require activa-
tion by a separate nitroreductase (14), but more recently it has
been proposed that DprE1 itself is able to activate BTZ in
a substrate-dependent fashion, prompting their characterization
as suicide inhibitors (13).
Efforts to structurally characterize M. tuberculosis DprE1 and
its interaction with inhibitors were hampered by the failure to
obtain sufﬁcient amounts of soluble recombinant protein. We
have been able to overcome this roadblock, facilitating crystal-
lization and structure determination of this target. Herein, we
report the crystal structure of M. tuberculosis DprE1, both in
the ligand-free form and bound to the BTZ-derived inhibitors
CT325 and CT319 (12).
Results
Coexpression with Mycobacterial Chaperonin Yields Soluble
Recombinant M. tuberculosis DprE1. Exploring coexpression with
chaperones we found that small amounts of soluble DprE1 could
be obtained using the Escherichia coli Tuner strain (Fig. S2A).
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The amount of DprE1 was consistently less than that of
chaperonin E. coli GroEL, and attempts to separate the two
products by chromatography were not successful. Coexpressing
DprE1 with the mycobacterial GroEL homolog Cpn60.1 and
the cochaperonin E. coli GroES (Fig. S2B) gave similarly dis-
appointing results. However, coexpression with M. tuberculosis
Cpn60.2 and E. coliGroES led to a signiﬁcant increase of soluble
DprE1 that could be readily separated from the chaperone
component by Ni-NTA and ion exchange chromatography,
yielding ∼5 mg of pure DprE1 from a 2-L culture (Fig. S2 C andD).
Although no FAD was added to cell lysates or puriﬁcation buf-
fers, concentrated and crystallized DprE1 showed the charac-
teristic intense yellow color of a FAD-containing protein in the
oxidized state.
Crystallographic Structure Determination and Overall Structure of
DprE1. Crystallization screens of puriﬁed M. tuberculosis DprE1
resulted in hits for several reservoir conditions, with crystals in
space group symmetries P21 or P64 (Tables S1 and S2). Phases
for the structure of ligand-free DprE1 were determined by sin-
gle-wavelength anomalous diffraction of an ytterbium-derivative
crystal of monoclinic DprE1 (two molecules per asymmetric unit;
Fig. S3 A and B and Table S1). Crystals of DprE1 in complex
with R-3-(nitroso)-N-(1-phenylethyl)-5-(triﬂuoromethyl) benza-
mide [CT325 (12)] were obtained both in the hexagonal and
monoclinic crystal forms, providing crystallographically in-
dependent views of the mode of inhibitor binding. In addition we
obtained crystals in complex with R-3-(nitro)-N-(1-phenylethyl)-
5-(triﬂuoromethyl) benzamide [CT319 (12)], which carries an
NO2 instead of the NO ring substituent of CT325.
The model of the hexagonal crystal form in complex with
CT319 comprises residues 7–461, with one disordered region
(residues 268 and 298), whereas the ligand-free forms and the
CT325 complex include two disordered regions in the chain
(Figs. 1 and 2 and Fig. S3C). The overall structure of DprE1
resembles closely that of FAD-containing alditol oxidase from
Streptomyces coelicolor (Protein Data Bank ID code 2VFR,
20% sequence identity, rmsd 3.0 Å for 374 aligned residues;
Fig. S3D) (15), its closest structural neighbor according to
distance matrix alignment using DALI (16). Alditol oxidase is
a representative of the vanillyl-alcohol oxidase (VAO) family
of oxidoreductases (17, 18).
The structure of DprE1 can be divided into the FAD-binding
domain (residues 7–196, 413–461) and the substrate-binding
domain (residues 197–412) (Fig. 1A and Fig. S3C). The FAD-
binding domain consists of an α+β fold, including two small
β-sheets (strands β1–β4 and β5–β9, respectively), and several
helices (α1–α4 and α11–α13). The cofactor is deeply buried in
the FAD-binding domain, with the isoalloxazine positioned at
the interface to the substrate-binding domain. In comparison
with the structure of alditol oxidase (15) and several other
structural homologs of DprE1, the conformation of FAD and its
immediate protein environment are highly conserved. However,
in DprE1 there is no covalent link between FAD and the protein,
as is typical for VAO enzymes (17). The substrate-binding do-
main consists of an extended, antiparallel β-sheet (strands β10–β
16) that faces the domain interface with ﬂavin at the center,
decorated by three extended helices (α5, α9, and α10) on the
back. This domain includes, in the ligand-free and CT325-bound
states, the two disordered regions.
The monoclinic and hexagonal crystal forms both display an
apparent dimer of DprE1 (Fig. S4A). Independent of symmetry,
dimerization is mediated by a twofold rotation axis that aligns
strands β5 (residues 80–84) of two copies of DprE1, related by
either space group symmetry (hexagonal lattice) or noncrystal-
lographic symmetry (monoclinic lattice), respectively. The di-
merization interface (buried solvent-accessible surface ∼340 Å2)
is stabilized by four main chain–main chain hydrogen bonds
and hydrophobic interactions between side chains of residues
Ile80, Ile83, and Phe108 (Fig. S4B). However, in sedimentation
velocity experiments we ﬁnd a single monomer peak, suggesting
that DprE1 does not dimerize appreciably in solution (Fig. S4C).
A
B
Scheme 1. Epimerization reaction of DPR to DPA and chemical structures of
inhibitors. (A) Chemical structures of BTZ043 (5), CT325 and CT319 (12), and
DNB1 (7). (B) Conversion of DPR to DPA involves oxidation and subsequent
reduction of the C2’ hydroxyl via a keto-intermediate (DPX). Relevant
enzymes and redox cofactors are indicated.
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Fig. 1. Fold of M. tuberculosis DprE1 and structural plasticity of surface
loops 269–297 and 316–330. (A) Ribbon diagram of DprE1 in the hexagonal
crystal form bound to the ligand CT319. FAD is shown in spheres (yellow
carbons), whereas CT319 is shown in violet spheres. Spheres in cyan indicate
the boundaries of the disordered region of residues 269–297. In the CT319-
bound form, residues 317–327 (cyan) form a helix. (B) Superposition of li-
gand-free (Apo-hex, salmon-colored) and inhibitor-bound (CT319-hex, light
blue) DprE1 of the hexagonal crystal form. The region of residues 316–322
(cyan) becomes ordered upon ligand binding. (C) Superposition of structures
obtained from monoclinic crystals (Apo-mcl: molecules A and B; Apo-mcl-
dmso: molecule A). The region of residues 268–283 (cyan) is ordered only in
molecule A of Apo-mcl-dmso.
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Structural Flexibility of DprE1. Electron density of both crystal
forms obtained for ligand-free DprE1 reveal disorder of two
surface loops in the substrate-binding domain. As a consequence
of the disorder, the active site is wide open in the ligand-free
form of the enzyme (Fig. 2A). At a maximum, residues 269–297
and 316–330 are lacking electron density, but the degree of
disorder or extent of the apparent gaps varies between the
monoclinic and hexagonal crystal forms. In the hexagonal form
of ligand-free DprE1, the ﬁrst region is disordered between
residues 269 and 297, and the second region lacks density for
residues 316–322 (Fig. 1B). In the monoclinic crystal form, the
density gap in the second region is considerably larger, affecting
residues 316–330 (Fig. 1C). In contrast, the density gap in the
ﬁrst region is smaller than in hexagonal crystals but varies be-
tween the two crystallographically distinct molecules of mono-
clinic DprE1: molecule A is lacking density for residues 269–283,
whereas in molecule B this gap extends from 269 to 293 (Fig.
1C). As a result, helix α6 (residues 292–298) only forms fully in
molecule A of monoclinic DprE1, whereas it appears as a two-
turn fragment in molecule B (Fig. 1C) and is altogether absent
from the structural model of hexagonal DprE1 (Fig. 1B).
However, there are two conditions under which we observe
ordering of region one or region two, but not both simulta-
neously. In the density for crystal Apo-mcl-dmso, the chain can
be completely traced between residues 268 and 284 for mole-
cule A (trace in cyan in Fig. 1C) but not for molecule B. The
peptide chain of this region is vaulting over the β-sheet of the
substrate-binding domain. Contacts with a symmetry-related
copy of molecule A in the center of this loop help stabilize this
particular conformation. Complete ordering of the second re-
gion (residues 316–330) is observed in hexagonal crystal of the
DprE1:CT319 complex, where residues 316–322 become or-
dered when CT319 is bound (trace in cyan in Fig. 1B, red
surface in Fig. 2B, and Fig. S5 A and B). As result, residues
317–327 form a three-turn helix (Fig. 1A, trace in cyan), al-
though it does not maintain strict α-helical geometry. Unit cell
parameters and crystal symmetry are unchanged between the
ligand-free and the CT325- and CT319-bound forms of hex-
agonal DprE1, despite different reservoir conditions (Table
S2). We, therefore, attribute ordering of residues 316–322 to
binding of CT319, the position of which in the active site differs
subtly but distinctly from that of CT325 (Fig. S5C).
Structures of the Complexes with BTZ Derivatives CT325 and CT319.
Although ﬂuorescence-based ligand-binding experiments (Fig.
S6A) demonstrated binding of the inhibitor BTZ043 (5) to
DprE1, crystals grown in the presence of BTZ043 did not re-
veal a bound ligand. Trefzer et al. (13) had suggested that
formation of the covalent complex between BTZ043 and
DprE1 requires prior conversion of the nitro group to the
nitroso form. To circumvent the need for inhibitor activation,
we synthesized the nitroso-benzothiazinone CT325 (12) for
cocrystallization experiments.
We obtained crystals of the DprE1:CT325 complex in both
the hexagonal and monoclinic crystal forms (CT325-hex3 and
CT325-mcl; Table S1) and recorded diffraction data to reso-
lutions of 2.4 and 2.6 Å (CuKα), respectively. A σA-weighted
Fo-Fc difference density map, calculated with model phases
before including the ligand in the model, displays prominent
density between ﬂavin and Cys387, the residue postulated to be
critical for BTZ-mediated inhibition of DprE1 activity and
BTZ-dependent cessation of mycobacterial growth (5) (Fig. 3
A and B). We observe bridging density between this cysteine
and the density enveloping the inhibitor model, evidence for
the formation of a covalent bond between CT325 and Cys387
in both crystal forms. However, the conformation of the
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Fig. 2. Molecular surfaces of ligand-free and inhibitor-bound DprE1 (hex-
agonal form). (A) Ligand-free DprE1 (Apo-hex), with FAD shown as spheres
(yellow carbons). The boundaries of the disordered regions are marked in
cyan, and the corresponding residue number is indicated. (B) CT319-bound
DprE1 (CT319-hex), where ordering of residues 316–322 (red surface) leads
to shielding of the active site from solvent, except for an access channel to
the re side of ﬂavin (arrow).
A
B
C
Fig. 3. Mode of binding of the nitroso derivative CT325 in the active site
of DprE1. (A) Stick model of FAD (yellow carbons), CT325 (blue carbons),
and selected protein residues (gray carbon) situated within a 4-Å cutoff
distance from the inhibitor. The σA-weighted FO-FC density map was cal-
culated on the basis of model phases before incorporation of CT325 in the
structural model and is contoured at 3.0σ above the mean. The structure
was reﬁned including a covalent link between Cys387 and CT325. (B)
Analogous view to A, showing the active site of molecule A in monoclinic
crystal CT325-mcl. The σA-weighted FO-FC density map is contoured at 2.0σ
above the mean. (C ) Schematic representation of CT325-protein contacts
in the active site of DprE1. Thick, hashed lines indicate noncovalent
interactions (van der Waals, hydrophobic), with interatomic distances
given in units of Å, whereas dashed lines indicate hydrogen bonds. For
graphical simplicity, only contacts of 4 Å or shorter have been included,
and Gln336 has been omitted from the view.
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phenylethyl group remained undeﬁned in the CT325 com-
plexes. While attempting to obtain diffraction data of the
DprE1:CT325 complex, we noticed that for some crystals the
bridging density between CT325 and Cys387 was notably ab-
sent, but the whole of the inhibitor molecule was deﬁned by
electron density, including the terminal phenylethyl group. We
suspected that the reactive nitroso group was unstable and may
have reverted to the more stable NO2 state before binding to the
protein, preventing formation of the covalent link to Cy387. To
test this assumption we generated crystals of CT319-bound
DprE1, which led to a noncovalent complex and ordering of the
loop region encompassing residues 316–322 over the active site
(Fig. S5A). As a result of the ordered state of residues 316–330,
the active site is shielded from bulk solvent (Fig. 2B), whereas in
the crystals of the DprE1:CT325 complex, the 316–330 loop
region remains in the disordered state.
The consistent density features obtained from crystals in dif-
ferent crystal forms allow one to unequivocally position CT325 in
the active site. The inhibitor adopts an extended conformation,
running parallel to the isoalloxazine. The triﬂuoromethyl moiety
packs against the backbone of residues 132–134, forming van der
Waals interactions with Gly133 and Lys134 (contact distances
between 3.3 Å and 3.9 Å; Fig. 3C and Fig. S7A), with additional
van der Waals contacts to the side chains of His132, Ser228, and
Lys367. The central benzamide group primarily interacts with
the ﬂavin (contact distances between 3.0 Å and 3.5 Å), with
Gly117 (3.2 Å), and with the side chain of Val365 (shortest
contact 3.7 Å). In addition the NO group forms a strong H-bond
(2.4 Å) with the amide of Asn385. Compared with the ligand-
free and CT319-bound state, the side chain of Cys387 is rotated
by 180° about the Cα–Cβ bond, facilitating the covalent bond to
the nitroso group, consistent with a previous prediction (12). The
terminal phenylethyl group is disordered in the CT325-bound
complex but well ordered for CT319, in which case the benzene
ring occupies a hydrophobic cavity formed by Leu363 and
Val365 in strand β16, Trp230 in strand β11, and by Leu317 and
Phe320 in the “316–322” loop (Fig. S7B). In the absence of loop
ordering, the cavity applies fewer constraints on the orientation
of the phenyl ring, and it is plausible that the terminal benzene
ring can assume variable orientations.
CT325 Inhibits Epimerization of DPR to DPA. Although CT319-de-
pendent inhibition of DprE1 had been previously demonstrated
for the Mycobacterium smegmatis ortholog (12), activity data
were not available to us for CT325. Incubating 14C-labeled
decaprenylphosphoryl-β-D-ribose (14C-DPR) with puriﬁed M.
tuberculosis DprE1 and DprE2 and analyzing reaction products
by TLC, we observe almost complete conversion of DPR to DPA
(Fig. 4A). When incubated with DprE1 alone, the DPR band is
reduced in intensity, and a distinct band appears below the DPR
band, representing the keto-intermediate DPX (Fig. 4 A and B
and Scheme 1A). No DPA is generated under these conditions.
Adding CT325 to the reaction mixture represses DPX formation
in a dose-dependent fashion (Fig. 4B), conﬁrming inhibition of
DprE1 activity by this inhibitor. Adding CT325 to a reaction
mixture containing both DprE1 and DprE2 represses conversion
to DPA (Fig. 4A). Furthermore, growth of the nonpathogenic
surrogate organisms M. smegmatis and Mycobacterium bovis ba-
cillus Calmette–Guérin are inhibited by CT325, with EC50 values
of 10.4 and 4.6 μg/mL, respectively (Fig. 4C).
In agreement with previous studies in which activity of
BTZ043 was assessed against M. smegmatis DrpE1 (5, 12, 13),
we ﬁnd that BTZ043 inhibits DPR to DPX conversion of
M. tuberculosis DprE1 (Fig. 4A). Thus, we are able to show that
that CT325 replicates the activity of BTZ043, in terms of in-
hibition of conversion of DPR to DPX (Fig. 4A) and in terms of
whole-cell activity (Fig. 4C), albeit with signiﬁcantly lower po-
tency than BTZ043.
Discussion
The recent controversy surrounding the report of a “totally drug
resistant” strain of M. tuberculosis in India (19) illustrates the
high stakes involved in the effort to control the TB pandemic, in
particular because this burden is carried primarily by resource-
limited health care systems in the developing world. Thus, the
discovery of benzothiazinones and dinitrobenzamides as novel
classes of potent inhibitors, effective against both drug-suscep-
tible and MDR/XDR forms of TB, and the identiﬁcation of their
target—DprE1—are signiﬁcant steps forward.
Epimerization of DPR is the ﬁnal step of DPA synthesis,
which involves the conversion of glucose to ribose-5-phosphate
via the pentose phosphate pathway, followed by synthesis of
phosphoribose-diphosphate (pRpp), nucleophilic replacement
of pyrophosphate by decaprenyl-phosphate, and removal of the
5′-phosphate to yield DPR (20). Although not ﬁrmly established, it
is likely that after attachment of the decaprenyl group, the DPA
precursor compounds are anchored into the cell membrane. This
raises the question of how DprE1 gains access to substrate.
DprE1 may need to be able to partially or wholly sequester the
decaprenyl moiety of the substrate. The wide-open active site of
ligand-free DprE1 and the two ﬂexible loops contrast with the
narrow, funnel-like access channel to the active site in the known
structures of ligand-free VAO enzymes, for instance in alditol
oxidase (Fig. S7C). Therefore, it seems plausible to invoke a link
between ﬂexibility of these loops and DPR binding.
Fig. 4. Assays probing inhibition of DprE1 and whole-cell activity of CT325.
(A) 14C-labeled DPR was incubated with DprE1 and DprE2, and epimerization
of DPR to DPA monitored by TLC. (B) As in A, but 14C-labeled substrate was
incubated with DprE1 alone, and conversion to the keto-intermediate DPX
was monitored. (C) CT325-induced inhibition of growth in batch cultures of
M. bovis bacillus Calmette–Guérin and M. smegmatis, monitored for 10 d
and 40 h, respectively, by measuring absorbance at 600 nm. SDs are derived
from two independent experiments.
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We propose that the structure of CT325-bound DprE1 is
a representative of the activated BTZ-target complex. The
structure and activity data demonstrate that CT325 binds to
DprE1 and that this interaction interferes with the conversion of
DPR to DPX in a dose-dependent fashion (Fig. 4B). We have
not shown explicitly that inhibition of DprE1 by CT325 com-
promises cell wall arabinan, but the suppression of DPR to DPA
conversion (Fig. 4A) and CT325’s whole-cell activity against
M. smegmatis and M. bovis bacillus Calmette–Guérin (Fig. 4C)
provides indirect evidence for such an effect.
Covalent binding of BTZ043 to DprE1 has been shown to be
dependent on Cys387: substitutions by Gly or Ser at this se-
quence position resulted in resistance to BTZ or DNB inhib-
itors (5, 12). The Fo-Fc difference electron density of the
inhibitor-bound structure of hexagonal and monoclinic DprE1
unequivocally indicate a covalent link between CT325 and
Cys387 (Fig. 3 A and B), and the shape of the bridging density
is consistent with a semimercaptal linkage. Density for the
triﬂuoromethyl group (8.7σ in CT325-mcl, 6.6 σ in CT325-
hex3), the electron-withdrawing ring substituent, is seen con-
sistently in all CT325 complex structures we obtained. Thus,
the triﬂuoromethyl seems to be a second key determinant of
CT325 binding, which together with the covalent bond and the
spatial constraints imposed by the active site unequivocally
position the ligand on the si side of ﬂavin. The terminal phe-
nylethyl moiety is only deﬁned in the noncovalent complex with
CT319. In the latter complex, ligand binding is accompanied by
ordering of the second surface loop (residues 316–322), which
closes the active site and provides additional contacts to sta-
bilize the phenylethyl in a deﬁned conformation (Figs. S5A and
S7B). Apart from the covalent link to Cys387, van der Waals
interactions dominate the network of noncovalent contacts
between enzyme and CT325 (Fig. 3C).
Given the key structural features shared between CT325 and
(activated) BTZ043, it is plausible to predict that binding of the
latter rests on the same key interactions—the covalent bond to
Cys387 and the van der Waals interactions of the triﬂuoromethyl
with the backbone of residues 132–134. Evidence from hexago-
nal crystals grown in the presence of (nominally) 3 mM BTZ043
is consistent with such reasoning. In a 2.5-Å density map, cal-
culated with CuKα diffraction data (BTZ-hex; Table S1 and Fig.
S6B), we observe distinct density peaks at the site of the tri-
ﬂuoromethyl group (5.5σ in the Fo-Fc difference map) and be-
tween the NO2 group and Cys387 (6.2σ), indicating the
alternative rotamer conformation of Cys387 that would facilitate
the semimercaptal. Although we cannot be certain that these
density features are due to a bound BTZ molecule, they align
with those of the CT325 complex and are consistent with the
observed saturation binding behavior of BTZ043 (Fig. S6A).
Overall, our structural study of DprE1 complexed with CT325
will provide a framework for the rational design of new BTZ-based
inhibitors targeting M. tuberculosis, whereas the complex with
CT319 indicates that a covalent link with DprE1 may be dispens-
able, provided that contacts with the disordered loop 316–322 and
other parts of the active site can be exploited to enhance afﬁnity.
Methods
Overexpression and Puriﬁcation of DprE1. DprE1 (Rv3790) was coexpressed
with chaperones from E. coli (GroES) and M. tuberculosis (CPN60.2) in E. coli
BL21 (DE3). Liquid cultures of E. coli, harboring pET28a-Rv3790 and pTrc-
60.2-GroES, were grown at 37 °C in LB broth (Difco) supplemented with
kanamycin (50 μg/mL) and ampicillin (100 μg/mL). At OD600nm 0.4–0.6 the
temperature was reduced to 16 °C, and protein expression of Rv3790 and
chaperones was induced by 0.5 mM isopropylthiogalactoside, followed by
incubation overnight (16 °C). Cells were harvested, washed with 0.85% sa-
line, and stored at −20 °C. Frozen cell pellets were thawed on ice and
resuspended in 30 mL of 50 mM NaH2PO4 (pH 8), 300 mM NaCl, and 10 mM
imidazole (buffer A), supplemented with EDTA-free protease inhibitor
mixture (Roche). The suspension was sonicated (Sonicator Ultrasonic Liquid
Processor XL; Misonix) on ice for a total time of 10 min (20-s pulses, 40-s cooling).
The lysate was centrifuged (27,000 × g, 40 min, 4 °C), and the supernatant passed
through a preequilibrated (buffer A) 1-mL Ni2+-charged His-Trap column (GE
Healthcare). The column was washed with 50 mL of buffer A plus 20 mM
imidazole, and the protein was eluted with a 50–300 mM gradient of im-
idazole. Fractions containing protein were dialyzed against 20 mM Tris·HCl
(pH 8.5), 10 mM NaCl, and 10% (vol/vol) glycerol (buffer B). After dialysis, the
protein was loaded on a 1-mL QHP ion exchange column (Amersham),
washed with 10 mL of buffer B with 50 mM NaCl, and eluted with a gradient
of 20-mM NaCl steps from 100 mM to 200 mM, in buffer B. Fractions con-
taining pure protein were dialyzed overnight against buffer B and concen-
trated to 35 mg/mL, by ultraﬁltration (10-kDa cutoff; Amicon Ultra).
Crystallization and Structure Determination. Crystals of DprE1 were grown by
sitting drop vapor diffusion in 96-well plates (Swissci), aided by a Mosquito
(TTP Labtech) liquid handling robot. Conditions producing diffracting crystals
of DprE1 are listed in Table S2. Crystals appeared after 1–3 d and could be
mounted from the drop and frozen in liquid nitrogen without additional
cryoprotection. The heavy atom derivative was obtained by immersing
monoclinic crystals for 12 min in mother liquor supplemented with 50 mM
ytterbium acetate, before mounting and ﬂash freezing. Diffraction data
were processed using XDS, XSCALE (21) (Table S1). Single-wavelength
anomalous diffraction data from the Yb-derivative crystal (Table S1) allowed
determination of the heavy atom positions [SHELXD (22)]. Heavy atom sites
were reﬁned and phases calculated [to 2.0 Å; SHARP, SOLOMON (23, 24)]
(Fig. S2A). Autobuilding [ARPWARP (25)] produced fragments of the two
molecules in the crystallographic asymmetric unit, sufﬁcient to derive the
noncrystallographic symmetry operator and enabling subsequent non-
crystallographic symmetry averaging [DM (26)] (Fig. S3B). Placing the initial
model into the unit cell of the hexagonal crystal form [PHASER (27), Apo-
hex; Table S1] helped to complete the model of DprE1 through manual
building and reﬁnement [COOT (28), REFMAC5 (26), PHENIX.REFINE (29)].
Structures of the inhibitor-bound enzyme were solved by molecular re-
placement [PHASER (27)], with model building and reﬁnement according to
standard protocols. Difference maps indicating the presence of CT325 or CT319
were calculated according to protein coordinates alone, before incorporation
of the ligand coordinates in the structural model. Figures were prepared using
PyMol (www.pymol.org), adopting the Corey-Pauling-Koltun (CPK) coloring
scheme: O, red; N, blue; S, sulfur; and C, as indicated in ﬁgure legends.
Activity Assays. The activity of DprE1, in the presence and absence of DprE2,
was assayed using radiolabeled 14C-DPR substrate, prepared as previously
described (30). Reaction mixtures contained 50 μg of (each) enzyme, 1 mM
FAD, 1mMATP, 1 mMNAD, and 1mMNADP, in 50mMMops (pH 7.9), 10 mM
MgCl2. To probe inhibition, enzymes were incubated with inhibitors (CT325
at 2-mM ﬁnal concentration, or BTZ043 at a ﬁnal concentration of 0.1 mM
in 3.13% dimethyl sulfoxide) for 30 min at 30 °C, followed by addition of
2,000 cpm of 14C-DPR in 5.5 μL of 1% IGEPAL. Reactions were allowed to
proceed for a further 90 min and then quenched with 350 μL of CHCl3:CH3OH
(2:1, vol/vol) and 55 μL H2O. The bottom layer of the biphase was dried
down, resuspended in 10 μL of CHCl3:CH3OH (2:1, vol/vol), and analyzed.
Samples were spotted on to a high-performance aluminum-backed TLC plate
(Merck) and separated in CHCl3:CH3OH:1M CH3COONH4: conc. NH4OH:H2O
(180:140:9:9:23) (vol/vol). Bands were visualized using a phosphor imaging
screen (Fuji) and a phosphor imager (Bio-Rad). CT325 was dissolved in di-
methyl sulfoxide to a concentration of 2 mg/mL and added to 2 mL of tryptic
soy broth in culture tubes to a ﬁnal concentration between 0 and 100 μg/mL
After the addition of 10 μL of a cell culture of stationary phaseM. smegmatis
mc2155 or M. bovis bacillus Calmette–Guérin, the cultures were incubated
at 37 °C for 40 h (M. smegmatis) or 10 d (M. bovis bacillus Calmette–Guérin)
with shaking. Culture growth was monitored by measuring absorbance at
600 nm (OD600) and the experiment was performed in duplicate.
Deposition of Coordinates and Structure Factors. Coordinates and structure
factors of DprE1 in ligand-free and CT325-bound forms have been deposited
in the Protein Data Bank (www.pdb.org).
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